Lung Cancer Update Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
May 18, 2025
Ram Govindan, a clinical investigator from Washington University specializing in non-small cell lung cancer, joins Stephen Liu from Georgetown University, who focuses on innovative immunotherapy treatments. They discuss groundbreaking advancements in combining chemotherapy with immunotherapy, showing improved survival rates. The conversation highlights the potential of bispecific therapies and antibody-drug conjugates, as well as the role of biomarkers in personalizing treatment. They also touch on emerging strategies like TDXD for HER2 mutations, shaping the future of lung cancer therapy.
AI Snips
Chapters
Transcript
Episode notes
Neoadjuvant Chemoimmunotherapy Benefits
- Neoadjuvant chemoimmunotherapy greatly increases pathologic complete response in resectable NSCLC compared to chemo alone.
- This approach shows durable improvements in event-free and overall survival, especially in high PD-L1 cases.
Adopt Bispecific Immunotherapies
- Utilize evolving bispecific immune therapies as a promising future strategy for lung cancer.
- Expand clinical access to bispecific antibodies like torlatomab, especially in small cell lung cancer.
Concurrent Durvalumab Ineffective
- Adding durvalumab concurrently with chemoradiation in locally advanced NSCLC did not improve outcomes compared to chemoradiation alone.
- Consolidation durvalumab after chemoradiation remains the standard based on survival benefit.